Clinical trials: Renal Transplant Patient
Chronic Renal Failure, Polycystic Kidney Disease
Mesenchymal Stem Cells Transplantation in Patients With Chronic Renal Failure Due to Polycystic Kidney Disease
This study was designed to provide confirmation of safety of mesenchymal stem cells (MSCs) therapy in chronic renal failure due to autosomal dominant polycystic kidney disease (ADPKD).
- Trial name
- NCT02166489
- Testing
- Intravenous injection autologous mesenchymal stem cells
- Where
- Iran
- Volunteers
- 6 people
- Sponsor
- Royan Institute
Acute Kidney Injury, Coronary Artery Bypass
Effect of Remote Ischemic Preconditioning on the Incidence of Acute Kidney Injury in Patients Undergoing Coronary Artery Bypass Graft Surgery
Background: Acute kidney injury (AKI) following coronary artery bypass graft (CABG) surgery is a major complication occurring in 1% to 53% of patients (depending on how it is defined) with the pooled rate of 18.2% and…
- Conditions
- Acute Kidney Injury, Coronary Artery Bypass, Ischemic Preconditioning
- Trial name
- NCT02981680
- Testing
- Remote Ischemic Preconditioning (RIPC)
- Where
- Iran
- Volunteers
- 180 people
- Sponsor
- Shiraz University of Medical Sciences
Kidney Disease, Kidney Failure
Hemodialysis in the Elderly (70yrs & Older)
This will be a prospective, single institution, parallel-group, single-blinded, randomized-controlled, two-arm, effectiveness study comparing autologous arteriovenous fistula versus hemodialysis access grafts in the elderly.
- Conditions
- Kidney Disease, Kidney Failure, Chronic Kidney Disease
- Trial name
- ELDERLY (NCT03065972)
- Testing
- Surgical fistula creation from patient's anatomy, Surgical Graft implant
- Where
- United States
- Volunteers
- 270 people
- Sponsor
- E. Peden, MD
Medication Adherence
Teen Adherence in KidnEy Transplant, Improving Tracking To Optimize Outcomes (Stage 1)
The overall goal of the Teen Adherence in KidnEy transplant Improving Tracking TO Optimize Outcomes (TAKE-IT TOO) study is to adapt the successful TAKE-IT intervention, aimed at improving medication adherence in adolescent kidney…
- Trial name
- TAKE-IT TOO (NCT02910661)
- Testing
- Focus Group
- Where
- 9 sites in United States, Canada
- Volunteers
- 95 people
- Sponsor
- Beth Foster
Kidney Transplant, Kidney Transplant Failure
Prevent Allosensitization in Patients Who Have Failed a First Renal Transplant (PART)
Kidney transplant is often the best treatment for people with kidney failure, but transplanted kidneys don't always last a lifetime.
- Conditions
- Kidney Transplant, Kidney Transplant Failure, Immunosuppresion
- Trial name
- NCT06802822
- Testing
- Prevention of Allosensitization
- Where
- Canada
- Volunteers
- 96 people
- Sponsor
- University of British Columbia
Decreased Immunologic Activity [PE], Influenza
Influenza A/H1N1/2009-adjuvanted Vaccine in Renal Disease Patients
In 2009, the pandemic influenza A/H1N1 accounted for worldwide recommendations about vaccination. There is no data concerning the immunogenicity nor the security of the adjuvanted-A/H1N1 vaccine in renal disease patients.
- Conditions
- Decreased Immunologic Activity [PE], Influenza, Rejection
- Trial name
- NCT01298102
- Testing
- Influenza A/H1N1 2009-AS03 adjuvanted (Pandemrix)
- Where
- Belgium
- Volunteers
- 185 people, healthy volunteers welcome
- Sponsor
- Erasme University Hospital
Kidney Transplant Immunosuppression
The Role of ImmuKnow® in the Management of Immunosuppressants in the Renal Transplant Patient
The purpose of this study is to demonstrate whether there are any outcome benefits of a serial ImmuKnow assays in the management of de novo renal transplant recipients.
- Trial name
- NCT01424345
- Testing
- adjustment of immunosuppressant dosages, adjustment of the dosages of immunosuppressants
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- CAMC Health System
Islets of Langerhans Transplantation, Diabetes Mellitus, Type 1
Calcineurin Inhibitor-free, Steroid-free Immunosuppressive Regimen in Simultaneous Islet-Kidney Transplantation for Uremic Type 1 Diabetic Patients
The investigators hypothesize that a calcineurin inhibitor-free, steroid-free, co-stimulatory blockade-based immunosuppressive regimen, in combination with a GLP-1 agonist, will reduce the islet mass required to achieve and…
- Conditions
- Islets of Langerhans Transplantation, Diabetes Mellitus, Type 1, Kidney Transplantation
- Trial name
- NCT01033500
- Testing
- Belatacept
- Where
- United States
- Sponsor
- University of Wisconsin, Madison
Kidney Transplantation
Rapamycin and Regulatory T Cells in Kidney Transplantation
The immune system response is mediated by the interaction between the antigen presenting cell (APC), CD4+ T helper cells (Th) and CD4+ CD25+ regulatory T cells, a subgroup of CD4+ T cell which express IL-2 receptor (CD25) and the…
- Trial name
- NCT01014234
- Testing
- Cyclosporins, Rapamycin
- Where
- Italy
- Volunteers
- 56 people
- Sponsor
- Fondazione IRCCS Policlinico San Matteo di Pavia
Diabetes Mellitus
Islet After Kidney Transplantation (IAK) in Patients With Type 1 Diabetes
The purpose of this study is to determine the safety of islet transplantation in patients with type 1 diabetes who have had a successful kidney transplant and have been maintained for at least three months on anti-rejection…
- Trial name
- NCT00708604
- Testing
- Islet Transplantation, Islet cell transplantation
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- City of Hope Medical Center
Chronic Kidney Disease (CKD)
A Study to Learn How Safe and Tolerable Vonsetamig is in Adult Patients With Chronic Kidney Disease (CKD) Who Need Kidney Transplantation and Are Highly Sensitized to Human Leukocyte Antigen (HLA)
The purpose of this study is to determine whether vonsetamig will safely decrease anti-HLA antibodies to allow for kidney transplantation.
- Trial name
- NCT05092347
- Testing
- Vonsetamig
- Where
- 10 sites in United States
- Volunteers
- 43 people
- Sponsor
- Regeneron Pharmaceuticals
Antibody-Mediated Rejection, Kidney Transplantation
Phase 2 Study of ALXN2030 in Patients With Antibody-Mediated Rejection After Kidney Transplantation
The primary objective of this study is to evaluate the efficacy of ALXN2030 compared with placebo on biopsy proven histologic resolution in participants with active or chronic active antibody-mediated rejection (AMR) at Week 52.
- Conditions
- Antibody-Mediated Rejection, Kidney Transplantation, Biopsy-proven Histologic Scores, AMR
- Trial name
- CONCORD (NCT06744647)
- Testing
- ALXN2030
- Where
- 51 sites in United States, Brazil and 6 more
- Volunteers
- 47 people
- Sponsor
- Alexion Pharmaceuticals, Inc.
End Stage Renal Disease, End Stage Liver Disease
Transplant Patient Registry of Liver, Kidney and/or Pancreas
This is a registry of data collected from patient records, both of those who have a condition which may require transplantation and those who have undergone transplantation of the liver, kidney and/or pancreas.
- Trial name
- NCT00238693
- Where
- United States
- Volunteers
- 13,767 people
- Sponsor
- Virginia Commonwealth University
Liver Transplant; Complications, Renal Complication of Procedure
Renal Outcomes Among Post Liver Transplantation Patients
To evaluate Renal outcomes among patients, post liver transplantation at Assiut university.
- Trial name
- NCT06123260
- Testing
- renal function tests
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Assiut University
Kidney Transplantation
Approach to Vascular Access After Renal Transplantation
The aim of the project is to assess the effect of functioning AVF in renal transplant patients on fibrosis, inflammation and LVH indicators.
- Trial name
- AVART (NCT04478968)
- Testing
- presence of AVF
- Where
- Poland
- Volunteers
- 150 people
- Sponsor
- Wroclaw Medical University
Type 1 Diabetes
Pancreas Allotransplantation for Diabetic Nephropathy and Mild Chronic REnal fAilure Stage Study
Current medical therapies are not able to prevent progression of established macroproteinuira (i.e. diabetic nephropathy) to end-stage renal failure in type 1 (insulin dependent) diabetic patients.
- Trial name
- PANCREAS (NCT01067950)
- Testing
- Isolated Pancreas Transplant, Intensive Insulin Therapy
- Where
- 7 sites in United States, Brazil and 3 more
- Volunteers
- 180 people
- Sponsor
- Nantes University Hospital
Vascular Stiffness
FGF21 Can Help Predicting Arterial Stiffness Measured by Cardio-ankle Vascular Index in Renal Transplant Patients
Chronic kidney disease(CKD) patients have high incidence of coronary artery problems event after renal transplantation. And remain a major cause of mortality. The major risk marker is arterial stiffness.
- Trial name
- CAVIFGF21 (NCT02704468)
- Testing
- CAVI and FGF-21
- Where
- Thailand
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Bangkok Metropolitan Administration Medical College and Vajira Hospital
Acute Rejection
Efficacy of Rituximab in Acute Cellular Rejection in Renal Transplant Patients
Acute kidney allograft rejection is the major cause for a loss of graft function and has a negative impact on long-term graft survival.
- Trial name
- RIACT (NCT01117662)
- Testing
- Rituximab
- Where
- 14 sites in Germany
- Volunteers
- 13 people
- Sponsor
- Hannover Medical School
Kidney Transplant
Study to Evaluate the Efficacy and Safety of Tacrolimus in Kidney Transplant Recipients (BLOSSOM)
The purpose of this study is to evaluate the efficacy and Safety after conversion to TacroBell SR cap. or TacroBell cap. in patients who in renal transplant patients undergoing maintenance therapy with Reference Tacrolimus.
- Trial name
- NCT04224350
- Testing
- TacroBell SR cap., Tacrolimus cap.
- Where
- South Korea
- Volunteers
- 184 people
- Sponsor
- Chong Kun Dang Pharmaceutical
Detection Accuracy, Patient Compliance
Reliability, Safety and Usability of the Transplantation Sensor System Combined With Myfortic® in Adult Kidney Transplant Patients
The main purpose of this exploratory trial is to evaluate the reliability, safety and usability of the Transplantation Sensor System when the Ingestible Event Marker (IEM) is given in combination with ECMPS 360 mg tablets in…
- Trial name
- NCT01320358
- Testing
- ECMPS-IEM
- Where
- 5 sites in Switzerland
- Volunteers
- 30 people
- Sponsor
- Novartis Pharmaceuticals